San Diego, California–(Newsfile Corp. – April 3, 2023) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid...
Vancouver, British Columbia–(Newsfile Corp. – March 31, 2023) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company“) today announces that it expects to...
<!– Name:DistributionId Value:8799351 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:500070338 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:8410a592-7bbd-4e7b-8e27-6e87ba45cf4b –> Zen Leaf...
Kelso, Washington–(Newsfile Corp. – March 30, 2023) – Vibe Cannabis is proud to announce the relocation of their Kelso dispensary, giving residents and visitors alike a...
Vancouver, British Columbia–(Newsfile Corp. – March 30, 2023) – GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) (“GHG” or the “Company”) is pleased to...
Edmonton, Alberta–(Newsfile Corp. – March 30, 2023) – Radient Technologies Inc. (TSXV: RTI) (OTC Pink: RDDTF) (“Radient” or the “Company“) is pleased to announce that the...
<!– Name:DistributionId Value:8797093 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5500 –> <!– Name:CustomerId Value:1267475 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:e74cc736-5f62-483a-8570-262d42ff230c –> Farmington, March...
<!– Name:DistributionId Value:8797705 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1199811 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:b91d623f-d551-4ebd-8f79-e8ea1334a47f –> New York,...
<!– Name:DistributionId Value:8797851 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1259337 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:6feda0b5-497b-4c91-b8e5-a38c1a53a716 –> New York,...
Initiated patient enrollment in a Phase II open-label clinical trial investigating the safety, tolerability, and efficacy of CardiolRx™ in patients with recurrent pericarditis – a debilitating...